Back to Authors

Danese, David S.

Mayo Clinic

Alnylam Pharmaceuticals (United States)

Citations 1

Modeling the Risk of Progression to Kidney Failure in Patients with Primary Hyperoxaluria Type 1 Treated with Lumasiran Relative to a Natural History Cohort Not Treated with Lumasiran
Danese, David S., Gansner, John M. , Lu, Jiandong , Milliner, Dawn S. , Lieske, John C. , Mara, Kristin C.

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 422-422

10.1681/asn.20213210s1422c Get It